Fatemeh Aghaei-meybodi - Department of internal medicine, Shaheed Sadoughi University of Medical Sciences,Yazd,Iran.
Nasim Namiranian - Diabetes Research Center, Shaheed Sadoughi University of Medical Sciences, Yazd,Iran.
Reihaneh Azizi - Diabetes Research Center, Shaheed Sadoughi University of Medical Sciences, Yazd,Iran.
Saeedeh Jam-Ashkezari - Diabetes Research Center, Shaheed Sadoughi University of Medical Sciences, Yazd,Iran.
Somaye Gholami

Introduction: Pioglitazone is one of the oral medications in type 2 diabetes (T2DM). Pioglitazone can reduce the inflammation process by activation of peroxisome proliferator-activated receptor gamma. The purpose of this study was to evaluate the effect of pioglitazone on asthma and diabetes related outcomes amongpatients with concurrent asthma and T2DM. Materials and Methods: We conducted a quasi-experimental study on 11 patients with concurrent asthma and T2DM in Yazd Diabetes Research Center 2014-2017. The inclusion criteria were patients between20-60 years old, at least one year with concurrent asthma and T2DM (documented with spirometer, bronchodilator test), ejection fraction more than 50%. Patients who were smoker, on oral corticosteroids, phenobarbital, methotrexate, rifampin, phenytoin, gemfibrozil and atorvastatin were excluded. Laboratory tests (FBS, HbA1c, 2hpp, leptin), spirometer test, exhaled nitric oxide were done before and after 10 weeks ofpioglitazone medication. All patients were visited 2 times in every treatment week. The before and after pioglitazone treatment differences were checked by paired ttestand Wilcoxon Rank sum test. Results: Among 373 patients, 15fulfilled the inclusion criteria of study and 11(5 male & 6 female) finished the study period. The mean (± SD) age of participants was 55.81± 7.66. The median of differences of leptin (P: 0.959), FEV1 to FVC (p: 0.21), FEV1 (P: 0.386), NO (P: 0.779), FVC percent (P: 0.447) before and afterpioglitazone treatment. The mean weight of patients at the beginning of study was 80.45 (±3.48) and after pioglitazone treatment was 82.18 (±3.06) which wasclinically significant (P: 0.053). Conclusion: Our finding suggested that pioglitazone may not be effective in the treatment and improvement of respiratory function in T2DM with concurrent asthma. Also the findings showed weight gain may be one of the worse outcomes of pioglitazone in diabetic patients which influence the glycemic and asthma control.

Bronchial Asthma, Thiazolidinediones, Type 2 Diabetes.